Bioavailability of temazepam in soft gelatin capsules.
1 Healthy volunteers received single doses of temazepam 30 mg in conventional gelatin capsules, suppositories or in solution. They experienced marked sedation and sleepiness. The onset of sleepiness was prompt after the administration of the solution; this latter showed the fastest absorption and gave the highest peak plasma levels. This observation led to the development of the soft gelatin capsule. 2 To assess bioavailability of the formulation, plasma levels of temazepam were determined in healthy volunteers after single oral administration of soft and hard capsules, and after seven consecutive night-time doses of the soft capsule. Absorption from the soft gelatin capsule was faster and produced earlier and higher peak plasma levels. There were no differences in relative availability. 3 The apparent half-life of temazepam after night-time administration was shorter than after morning administration, but no change was observed between the first and seventh night-time doses.
D014151:Anti-Anxiety Agents / Q000378:metabolism*; D001682:Biological Availability; D002214:Capsules; D006207:Half-Life; D006801:Humans; D013693:Temazepam / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*
D014151:Anti-Anxiety Agents; D002214:Capsules; D013693:Temazepam